Related Experiment Video
Updated: Jun 19, 2025
07:17
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
1.1K
Non-Hodgkin's Anaplastic Large T-Cell Lymphoma: A Case Report.
Gabriele A Halpern1, Luiza Miziara Brochi2, Cintia Gomes3
1General Practice, University Center of Volta Redonda, Volta Redonda, BRA.
Cureus
|July 25, 2024
Summary
Anaplastic large T/null cell lymphoma (ALCL), an aggressive non-Hodgkin's lymphoma (NHL), was diagnosed in a young male. Chemotherapy led to a complete remission, highlighting effective treatment options for this rare lymphoma subtype.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Anaplastic large T/null cell lymphoma (ALCL) is an aggressive non-Hodgkin's lymphoma (NHL) predominantly affecting young males.
- Early diagnosis and understanding of ALCL's clinical presentation are crucial for effective management.
Observation:
- A 32-year-old male presented with severe ulcerated axillary adenopathy, subcutaneous nodules, and sepsis.
- Diagnostic confirmation of ALCL was achieved through bone marrow aspirate and biopsy.
- Immunohistochemistry revealed neoplastic cells positive for CD3 (focal), CD30 (diffuse), ALK-1 (diffuse), and EMA (multifocal).
Findings:
- The patient received chemotherapy, resulting in a complete response and disease remission.
- This case underscores the diagnostic features and clinical presentation of ALCL.
Implications:
- Reporting rare NHL subtypes like ALCL increases awareness among clinicians.
- Discussion of current treatment regimens and their remission rates can guide therapeutic strategies.
- This case highlights the potential for successful treatment outcomes in aggressive lymphoma with timely intervention.
